View More Recent Stories
-
The election implications for healthcare technology and distribution stocks - BofA
-
Murchinson Nominates Two Candidates to Nano Dimension’s (NNDM) Board
-
Barclays on McKesson (MCK): 'We'd expect modest outperformance'
-
McKesson (MCK) PT Lowered to $579 at Deutsche Bank
-
Baird Downgrades McKesson (MCK) to Neutral
-
McKesson (MCK) PT Raised to $85 at Jefferies
-
McKesson (MCK) PT Lowered to $603 at Baird
-
McKesson (MCK) PT Lowered to $665 at Leerink Partners
-
TD Cowen Reiterates Buy Rating on McKesson (MCK), Says Share Reaction is 'Overdone'
-
McKesson (MCK) Declines After Issuing Soft Second Quarter EPS Guidance
-
BofA Securities Reiterates Buy Rating on McKesson (MCK) Following Sale of Rexall and Well.ca
-
McKesson (MCK) Announces Sale of Rexall and Well.ca Businesses to Birch Hill Equity Partners
-
TD Cowen Reiterates Buy Rating on McKesson (MCK)
-
McKesson (MCK) to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute’s Core Ventures
-
McKesson (MCK) Is Said To Be In Talks To Buy Florida Cancer Chain - Bloomberg
-
McKesson (MCK) options active on 10K contracts as share price down 11.5%
-
Midday movers: Eli Lilly, Robinhood and Zillow rise; Warner Bros, Fastly, Bumble fall
-
McKesson (MCK) PT Raised to $570 at Mizuho
-
McKesson (MCK) Tops Q1 EPS by 67c; raises guidance
-
McKesson (MCK) call put ratio 1.8 calls to 1 put into quarter results and outlook
-
McKesson (MCK) call put ratio 1 call to 1.9 puts into quarter results
-
McKesson (MCK) Raises Quarterly Dividend 14.5% to $0.71; 0.5% Yield
-
McKesson (MCK) PT Raised to $694 at Baird
-
McKesson (MCK) PT Raised to $74 at Jefferies
-
McKesson (MCK) PT Raised to $670 at Argus
-
McKesson (MCK) PT Lowered to $73 at Jefferies
